Ira Shafran

2.5k total citations
44 papers, 1.2k citations indexed

About

Ira Shafran is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Ira Shafran has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 24 papers in Epidemiology and 15 papers in Surgery. Recurrent topics in Ira Shafran's work include Inflammatory Bowel Disease (32 papers), Microscopic Colitis (13 papers) and Pharmacological Effects of Natural Compounds (8 papers). Ira Shafran is often cited by papers focused on Inflammatory Bowel Disease (32 papers), Microscopic Colitis (13 papers) and Pharmacological Effects of Natural Compounds (8 papers). Ira Shafran collaborates with scholars based in United States, United Kingdom and Canada. Ira Shafran's co-authors include Saleh A. Naser, David T. Rubin, William Chamberlin, William J. Sandborn, Brian G. Feagan, Bruce E. Sands, Silvio Danese, Edward V. Loftus, Geert D’Haens and Remo Panaccione and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and Gastrointestinal Endoscopy.

In The Last Decade

Ira Shafran

40 papers receiving 1.2k citations

Peers

Ira Shafran

EPIDE

GENET

SURGE

IMMUN

Alicia C Marín Spain

Roberta Pica Italy

Stephen Bridger United Kingdom

Karel Geboes Belgium

Peter J.P. Croucher Germany

Robert P. McCabe United States

Adrián G. McNicholl Spain

G Järnerot Sweden

Offer Cohavy United States

K-H MEYER ZUM BÜSCHENFELDE Germany

Alicia C Marín Spain

Ira Shafran

409 ×0.5

EPIDE

515 ×0.7

GENET

436 ×1.5

SURGE

290 ×1.0

IMMUN

124 ×0.6

Citations per year, relative to Ira Shafran Ira Shafran (= 1×) peers Alicia C Marín

Countries citing papers authored by Ira Shafran

Since Specialization

Citations

This map shows the geographic impact of Ira Shafran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ira Shafran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ira Shafran more than expected).

Fields of papers citing papers by Ira Shafran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ira Shafran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ira Shafran. The network helps show where Ira Shafran may publish in the future.

Co-authorship network of co-authors of Ira Shafran

This figure shows the co-authorship network connecting the top 25 collaborators of Ira Shafran. A scholar is included among the top collaborators of Ira Shafran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ira Shafran. Ira Shafran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loftus, Edward V., Brian G. Feagan, Remo Panaccione, et al.. (2020). Long‐term safety of vedolizumab for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 52(8). 1353–1365. 119 indexed citations

Kuenstner, J. Todd, Raghava Potula, Tim J. Bull, et al.. (2020). Presence of Infection by Mycobacterium avium subsp. paratuberculosis in the Blood of Patients with Crohn’s Disease and Control Subjects Shown by Multiple Laboratory Culture and Antibody Methods. Microorganisms. 8(12). 2054–2054. 18 indexed citations

Melmed, Gil, Marla C. Dubinsky, David T. Rubin, et al.. (2018). Utility of video capsule endoscopy for longitudinal monitoring of Crohn’s disease activity in the small bowel: a prospective study. Gastrointestinal Endoscopy. 88(6). 947–955.e2. 32 indexed citations

Shafran, Ira, et al.. (2017). P-035 Efficacy of Vedolizumab Used in Combination with Mercaptopurine as a Therapy for Crohn's Disease: A Four Patient Case Study. Inflammatory Bowel Diseases. 23.

Vermeire, Séverine, Edward V. Loftus, J F Colombel, et al.. (2017). DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. Journal of Crohn s and Colitis. 11(suppl_1). S39–S39. 3 indexed citations

Loftus, Edward V., Jean‐Frédéric Colombel, Brian G. Feagan, et al.. (2016). Long-term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn s and Colitis. 11(4). jjw177–jjw177. 167 indexed citations

Sands, Bruce E., Ira Shafran, Francis A. Farraye, et al.. (2015). Sa1273 Efficacy and Safety of Retreatment With Vedolizumab in Patients With Crohn's Disease. Gastroenterology. 148(4). S–278. 2 indexed citations

Osterman, Mark T., Faten Aberra, Raymond K. Cross, et al.. (2014). Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 12(11). 1887–1893.e3. 65 indexed citations

Shafran, Ira, et al.. (2012). The Use of Wireless Capsule Endoscopy in Community Practice: An 11 Year Experience. Inflammatory Bowel Diseases. 18. S68–S68. 1 indexed citations

10.

Shafran, Ira, et al.. (2010). Adjunctive Antibiotic Therapy with Rifaximin May Help Reduce Crohn’s Disease Activity. Digestive Diseases and Sciences. 55(4). 1079–1084. 27 indexed citations

11.

Rossi, Claudia Peña, et al.. (2009). Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterology. 9(1). 22–22. 37 indexed citations

12.

Shafran, Ira, et al.. (2009). Mobile and Web-Based Application for IBD Tracking. Inflammatory Bowel Diseases. 15. S40–S40. 2 indexed citations

13.

Burakoff, Robert, Charles F. Barish, Dennis Riff, et al.. (2006). A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohnʼs disease. Inflammatory Bowel Diseases. 12(7). 558–565. 82 indexed citations

14.

Shafran, Ira & Lorin K. Johnson. (2005). An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Current Medical Research and Opinion. 21(8). 1165–1169. 48 indexed citations

15.

Shafran, Ira, Lorin K. Johnson, Lynne Hamm, & Robert H. Murdock. (2003). EFFICACY AND TOLERABILITY OF RIFAXIMIN, A NONABSORBED ORAL ANTIBIOTIC, IN THE TREATMENT OF ACTIVE CROHNʼS DISEASE: RESULTS OF AN OPEN-LABEL STUDY. The American Journal of Gastroenterology. 98. S250–S250. 2 indexed citations

16.

Shafran, Ira, et al.. (2002). Seroreactivities Against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 Antigens in Crohn's Disease Patients. Digestive Diseases and Sciences. 47(9). 2079–2081. 16 indexed citations

17.

Shafran, Ira, et al.. (2002). Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Digestive and Liver Disease. 34(1). 22–28. 79 indexed citations

18.

Naser, Saleh A., et al.. (2002). In situ identification of mycobacteria in Crohn's disease patient tissue using confocal scanning laser microscopy. Molecular and Cellular Probes. 16(1). 41–48. 40 indexed citations

19.

Chamberlin, William, David Y. Graham, Kristina G. Hultén, et al.. (2001). Mycobacterium aviumsubsp.paratuberculosisas one cause of Crohn’s disease. Alimentary Pharmacology & Therapeutics. 15(3). 337–346. 139 indexed citations

20.

Shafran, Ira, Claudia Romero, Christopher Piromalli, et al.. (2000). Use of short-term culture for identification of Mycobacterium avium subsp. paratuberculosis in tissue from Crohn's disease patients. Clinical Microbiology and Infection. 6(6). 303–307. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact